Literature DB >> 19959243

Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.

Merilyne C Waldo1, Laurie Woodward, Lawrence E Adler.   

Abstract

Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19959243      PMCID： PMC2815213          DOI： 10.1016/j.psychres.2009.01.025

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  9 in total

1.  Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval.

Authors:  H T Nagamoto; L E Adler; M C Waldo; R Freedman
Journal:  Biol Psychiatry       Date:  1989-03-01       Impact factor: 13.382

2.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Authors:  Karla B Mihalak; F Ivy Carroll; Charles W Luetje
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

3.  Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.

Authors:  Lawrence E Adler; Ellen M Cawthra; Kara A Donovan; Josette G Harris; Herbert T Nagamoto; Ann Olincy; Merilyne C Waldo
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

4.  Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

Authors:  R Scott Obach; Anne E Reed-Hagen; Suzanne S Krueger; Beth J Obach; Thomas N O'Connell; Kathleen S Zandi; Sandra Miller; Jotham W Coe
Journal:  Drug Metab Dispos       Date:  2005-10-12       Impact factor: 3.922

5.  Cholinergic gating of response to auditory stimuli in rat hippocampus.

Authors:  V Luntz-Leybman; P C Bickford; R Freedman
Journal:  Brain Res       Date:  1992-07-31       Impact factor: 3.252

6.  Normalization of auditory physiology by cigarette smoking in schizophrenic patients.

Authors:  L E Adler; L D Hoffer; A Wiser; R Freedman
Journal:  Am J Psychiatry       Date:  1993-12       Impact factor: 18.112

7.  Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.

Authors:  Lawrence E Adler; Ann Olincy; Ellen M Cawthra; Kara A McRae; Josette G Harris; Herbert T Nagamoto; Merilyne C Waldo; Mei-Hua Hall; Amanda Bowles; Laurie Woodward; Randal G Ross; Robert Freedman
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

8.  Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics.

Authors:  L E Adler; L J Hoffer; J Griffith; M C Waldo; R Freedman
Journal:  Biol Psychiatry       Date:  1992-10-01       Impact factor: 13.382

9.  Neurobiological studies of sensory gating in schizophrenia.

Authors:  R Freedman; L E Adler; G A Gerhardt; M Waldo; N Baker; G M Rose; C Drebing; H Nagamoto; P Bickford-Wimer; R Franks
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306
  9 in total
  10 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

3.  Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.

Authors:  Sungwon Roh; Susanne S Hoeppner; David Schoenfeld; Catherine A Fullerton; Luke E Stoeckel; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

4.  A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.

Authors:  Mahtab Karkhane Yousefi; Timothy D Folsom; S Hossein Fatemi
Journal:  J Addict Res Ther       Date:  2011-12-20

5.  Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.

Authors:  Karen E Stevens; Kevin S Choo; Jerry A Stitzel; Michael J Marks; Catherine E Adams
Journal:  Brain Res       Date:  2014-01-23       Impact factor: 3.252

6.  A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia.

Authors:  Akihiro Shiina; Yukihiko Shirayama; Tomihisa Niitsu; Tasuku Hashimoto; Taisuke Yoshida; Tadashi Hasegawa; Tadashi Haraguchi; Nobuhisa Kanahara; Tetsuya Shiraishi; Mihisa Fujisaki; Goro Fukami; Michiko Nakazato; Masaomi Iyo; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-06-24       Impact factor: 3.455

Review 7.  Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Authors:  Douglas L Boggs; Jon Carlson; Jose Cortes-Briones; John H Krystal; D Cyril D'Souza
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 8.  Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Authors:  J Smucny; K E Stevens; A Olincy; J R Tregellas
Journal:  Transl Psychiatry       Date:  2015-06-23       Impact factor: 6.222

9.  Selective 5HT3 antagonists and sensory processing: a systematic review.

Authors:  Eirini Tsitsipa; Jonathan Rogers; Sebastian Casalotti; Clara Belessiotis-Richards; Olga Zubko; Rimona S Weil; Robert Howard; James A Bisby; Suzanne Reeves
Journal:  Neuropsychopharmacology       Date:  2022-01-11       Impact factor: 8.294

10.  Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis.

Authors:  Saeed Ahmed; Sanya Virani; Vijaya P Kotapati; Ramya Bachu; Mahwish Adnan; Ali M Khan; Aarij Zubair; Gulshan Begum; Jeevan Kumar; Mustafa Qureshi; Rizwan Ahmed
Journal:  Front Psychiatry       Date:  2018-09-19       Impact factor: 4.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.